RSS feed

Publications (original articles or review articles) published in 2017 from OUS - Section for Preventive Cardiology

22 publications found

Aune D, Giovannucci E, Boffetta P, Fadnes LT, Keum N, Norat T, Greenwood DC, Riboli E, Vatten LJ, Tonstad S (2017)
Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality-a systematic review and dose-response meta-analysis of prospective studies
Int J Epidemiol, 46 (3), 1029-1056
DOI 10.1093/ije/dyw319, PubMed 28338764

Aune D, Schlesinger S, Henriksen T, Saugstad OD, Tonstad S (2017)
Physical activity and the risk of preterm birth: a systematic review and meta-analysis of epidemiological studies
BJOG, 124 (12), 1816-1826
DOI 10.1111/1471-0528.14672, PubMed 28374930

Aune D, Sen A, Leitzmann MF, Norat T, Tonstad S, Vatten LJ (2017)
Body mass index and physical activity and the risk of diverticular disease: a systematic review and meta-analysis of prospective studies
Eur J Nutr, 56 (8), 2423-2438
DOI 10.1007/s00394-017-1443-x, PubMed 28393286

Aune D, Sen A, ó'Hartaigh B, Janszky I, Romundstad PR, Tonstad S, Vatten LJ (2017)
Resting heart rate and the risk of cardiovascular disease, total cancer, and all-cause mortality - A systematic review and dose-response meta-analysis of prospective studies
Nutr Metab Cardiovasc Dis, 27 (6), 504-517
DOI 10.1016/j.numecd.2017.04.004, PubMed 28552551

Aune D, Sen A, Schlesinger S, Norat T, Janszky I, Romundstad P, Tonstad S, Riboli E, Vatten LJ (2017)
Body mass index, abdominal fatness, fat mass and the risk of atrial fibrillation: a systematic review and dose-response meta-analysis of prospective studies
Eur J Epidemiol, 32 (3), 181-192
DOI 10.1007/s10654-017-0232-4, PubMed 28194602

Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS (2017)
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
Circulation, 137 (4), 338-350
DOI 10.1161/CIRCULATIONAHA.117.032235, PubMed 29133605

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Monique Verschuren WM, Vlachopoulos C, Wood DA, Luis Zamorano J, Additional Contributor, Cooney MT (2017)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Rev Esp Cardiol (Engl Ed), 70 (2), 115
DOI 10.1016/j.rec.2017.01.002, PubMed 29389351

Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van Hout B, Villa G, Qian Y, Somaratne R, Sabatine MS (2017)
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
JAMA Cardiol, 2 (10), 1069-1078
DOI 10.1001/jamacardio.2017.2762, PubMed 28832867

Giugliano RP, Keech A, Murphy SA, Huber K, Tokgozoglu SL, Lewis BS, Ferreira J, Pineda AL, Somaratne R, Sever PS, Pedersen TR, Sabatine MS (2017)
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial
JAMA Cardiol, 2 (12), 1385-1391
DOI 10.1001/jamacardio.2017.3944, PubMed 29117276

Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Robinson JG, Honarpour N, Wasserman SM, Ott BR, EBBINGHAUS Investigators (2017)
Cognitive Function in a Randomized Trial of Evolocumab
N Engl J Med, 377 (7), 633-643
DOI 10.1056/NEJMoa1701131, PubMed 28813214

Giugliano RP, Mach F, Zavitz K, Kurtz C, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Honarpour N, Wasserman SM, Ott BR, EBBINGHAUS Investigators (2017)
Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial
Clin Cardiol, 40 (2), 59-65
DOI 10.1002/clc.22678, PubMed 28207168

Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS, FOURIER Investigators (2017)
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Lancet, 390 (10106), 1962-1971
DOI 10.1016/S0140-6736(17)32290-0, PubMed 28859947

Greve AM, Bang CN, Boman K, Egstrup K, Forman JL, Kesäniemi YA, Ray S, Pedersen TR, Best P, Rajamannan NM, Wachtell K (2017)
Effect Modifications of Lipid-Lowering Therapy on Progression of Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study)
Am J Cardiol, 121 (6), 739-745
DOI 10.1016/j.amjcard.2017.12.011, PubMed 29361285

Klemsdal TO, Gjelsvik B, Elling I, Johansen S, Kjeldsen SE, Kristensen O, Madsen S, Njolstad I, Selmer R, Tonstad S, Voie H (2017)
New guidelines for the prevention of cardiovascular disease
Tidsskr. Nor. Laegeforen., 137 (16), 1164-1168

Mathisen TF, Rosenvinge JH, Pettersen G, Friborg O, Vrabel K, Bratland-Sanda S, Svendsen M, Stensrud T, Bakland M, Wynn R, Sundgot-Borgen J (2017)
The PED-t trial protocol: The effect of physical exercise -and dietary therapy compared with cognitive behavior therapy in treatment of bulimia nervosa and binge eating disorder
BMC Psychiatry, 17 (1), 180
DOI 10.1186/s12888-017-1312-4, PubMed 28494809

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
N Engl J Med, 376 (18), 1713-1722
DOI 10.1056/NEJMoa1615664, PubMed 28304224

Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR (2017)
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Lancet Diabetes Endocrinol, 5 (12), 941-950
DOI 10.1016/S2213-8587(17)30313-3, PubMed 28927706

Thorolfsdottir RB, Sveinbjornsson G, Sulem P, Helgadottir A, Gretarsdottir S, Benonisdottir S, Magnusdottir A, Davidsson OB, Rajamani S, Roden DM, Darbar D, Pedersen TR, Sabatine MS, Jonsdottir I, Arnar DO, Thorsteinsdottir U, Gudbjartsson DF, Holm H, Stefansson K (2017)
A Missense Variant in PLEC Increases Risk of Atrial Fibrillation
J Am Coll Cardiol, 70 (17), 2157-2168
DOI 10.1016/j.jacc.2017.09.005, PubMed 29050564

Tonstad S (2017)
[Statin intolerance]
Tidsskr Nor Laegeforen, 137 (1), 36-38
DOI 10.4045/tidsskr.16.0646, PubMed 28073228

Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E, Ramaswami U (2017)
Statins for children with familial hypercholesterolemia
Cochrane Database Syst Rev, 7 (7), CD006401
DOI 10.1002/14651858.CD006401.pub4, PubMed 28685504

Aambo A, Klemsdal TO (2017)
Cardiovascular disease and diabetes by African or Asian background
Tidsskr. Nor. Laegeforen., 137 (22), 1790-1794

Aambø A, Klemsdal TO (2017)
Cardiovascular disease and diabetes in patients with African or Asian background
Tidsskr Nor Laegeforen, 137 (22)
DOI 10.4045/tidsskr.16.0680, PubMed 29181932